TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Auto-Continuous Positive Airway Pressure Device(Auto-CPAP) With Conventional Fixed CPAP in Chinese Patients With Obstructive Sleep Apnea (OSA)
Brief Summary: AutoCPAP would lead to better compliance than FixCPAP


Options:
A: Arm Label: C-flex; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP (REMstar (Respironics)) | Arm Label: A-flex; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP (REMstar (Respironics)) | Arm Label: Auto-CPAP; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: CPAP (REMstar (Respironics)); Assigned to Arm(s): A-flex, C-flex
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: BiPap auto with Fi Flex | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard CPAP | Intervention Type: DEVICE; Name: BiPap auto with Fi Flex; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Standard CPAP; Assigned to Arm(s): 2
C: Intervention Type: DEVICE; Name: AutoCPAP; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: FixCPAP; Assigned to Arm(s): N/A
D: Arm Label: Fixed pressure; Type: ACTIVE_COMPARATOR; Interventions: Device: S8 Spirit 2, Device: Somnosmart 2, Device: Remstar Auto | Arm Label: Auto-adjusting pressure; Type: ACTIVE_COMPARATOR; Interventions: Device: S8 Spirit 2, Device: Somnosmart 2, Device: Remstar Auto | Intervention Type: DEVICE; Name: S8 Spirit 2; Assigned to Arm(s): Auto-adjusting pressure, Fixed pressure | Intervention Type: DEVICE; Name: Somnosmart 2; Assigned to Arm(s): Auto-adjusting pressure, Fixed pressure | Intervention Type: DEVICE; Name: Remstar Auto; Assigned to Arm(s): Auto-adjusting pressure, Fixed pressure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A
B: Arm Label: 10 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 25 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 75 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 150 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Ixekizumab, Drug: Placebo | Arm Label: 120 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Arm Label: 80 mg Ixekizumab; Type: EXPERIMENTAL; Interventions: Biological: Ixekizumab | Intervention Type: BIOLOGICAL; Name: Ixekizumab; Assigned to Arm(s): 10 mg Ixekizumab, 120 mg Ixekizumab, 150 mg Ixekizumab, 25 mg Ixekizumab, 75 mg Ixekizumab, 80 mg Ixekizumab, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
D: Arm Label: Placebo Comparator: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Voclosporin 0.2 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.3 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.4 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Intervention Type: DRUG; Name: voclosporin; Assigned to Arm(s): Voclosporin 0.2 mg/kg po BID, Voclosporin 0.3 mg/kg po BID, Voclosporin 0.4 mg/kg po BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
B: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A
C: Arm Label: CNTO1275 (ustekinumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: CNTO 1275 63 mg, Drug: Placebo | Intervention Type: DRUG; Name: CNTO 1275 63 mg; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): CNTO1275 (ustekinumab), Placebo
D: Intervention Type: DRUG; Name: Certolizumab Pegol (CDP870); Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: etanercept, Drug: Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): B | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: Tildrakizumab 200 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 200 mg, Drug: Etanercept Placebo | Arm Label: Tildrakizumab 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Tildrakizumab 100 mg, Drug: Etanercept Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept Placebo | Arm Label: Etanercept 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tildrakizumab Placebo, Drug: Etanercept 50 mg | Intervention Type: DRUG; Name: Tildrakizumab 200 mg; Assigned to Arm(s): Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Tildrakizumab 100 mg; Assigned to Arm(s): Tildrakizumab 100 mg | Intervention Type: DRUG; Name: Tildrakizumab Placebo; Assigned to Arm(s): Etanercept 50 mg, Placebo | Intervention Type: DRUG; Name: Etanercept Placebo; Assigned to Arm(s): Placebo, Tildrakizumab 100 mg, Tildrakizumab 200 mg | Intervention Type: DRUG; Name: Etanercept 50 mg; Assigned to Arm(s): Etanercept 50 mg
C: Arm Label: Placebo Comparator: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Voclosporin 0.2 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.3 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Arm Label: Voclosporin 0.4 mg/kg po BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: voclosporin | Intervention Type: DRUG; Name: voclosporin; Assigned to Arm(s): Voclosporin 0.2 mg/kg po BID, Voclosporin 0.3 mg/kg po BID, Voclosporin 0.4 mg/kg po BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Comparator: 1
D: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)
B: Arm Label: PF-06700841 Oral Solution/Suspension; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 oral solution/suspension | Arm Label: PF-06700841 Tablet; Type: EXPERIMENTAL; Interventions: Drug: PF-06700841 tablet | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: PF-06700841 oral solution/suspension; Assigned to Arm(s): PF-06700841 Oral Solution/Suspension | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: PF-06700841 tablet; Assigned to Arm(s): PF-06700841 Tablet
C: Arm Label: AIN457 300 mg; Type: EXPERIMENTAL; Interventions: Drug: AIN457 300 mg | Arm Label: Ustekinumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: ustekinumab 45/90 mg, Drug: placebo secukinumab | Intervention Type: DRUG; Name: AIN457 300 mg; Assigned to Arm(s): AIN457 300 mg | Intervention Type: DRUG; Name: ustekinumab 45/90 mg; Assigned to Arm(s): Ustekinumab | Intervention Type: DRUG; Name: placebo secukinumab; Assigned to Arm(s): Ustekinumab
D: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
B: Arm Label: Ixekizumab Q2W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Ixekizumab Q4W; Type: EXPERIMENTAL; Interventions: Drug: Ixekizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Adalimumab Q2W; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab | Intervention Type: DRUG; Name: Ixekizumab; Assigned to Arm(s): Ixekizumab Q2W, Ixekizumab Q4W | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab Q2W
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acitretin | Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Experimental | Intervention Type: DRUG; Name: Acitretin; Assigned to Arm(s): Control
D: Arm Label: Adalimumab (Part A); Type: ACTIVE_COMPARATOR; Interventions: Biological: adalimumab, Drug: placebo for risankizumab | Arm Label: Risankizumab (Part A); Type: EXPERIMENTAL; Interventions: Drug: risankizumab, Biological: placebo for adalimumab | Intervention Type: DRUG; Name: risankizumab; Assigned to Arm(s): Risankizumab (Part A) | Intervention Type: BIOLOGICAL; Name: adalimumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: DRUG; Name: placebo for risankizumab; Assigned to Arm(s): Adalimumab (Part A) | Intervention Type: BIOLOGICAL; Name: placebo for adalimumab; Assigned to Arm(s): Risankizumab (Part A)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy in ANCA Associated Systemic Vasculitis
Brief Summary: The aim of IMPROVE is to define the optimal maintenance therapy for ANCA-associated vasculitides (AASV) by comparing the AZA (standard regimen) with MMF in terms of efficacy, i.e. in preventing relapses.

HYPOTHESIS :

MMF might be more effective than azathioprine as maintenance drug in AASV patients, reducing by 50% relapse rate, with a same frequency of adverse effects


Options:
A: Arm Label: Rituximab Maintenance; Type: EXPERIMENTAL; Interventions: Biological: Rituximab | Arm Label: Azathioprine Maintenance; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Rituximab Maintenance | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Azathioprine Maintenance
B: Arm Label: mycophenolate mofetil; Type: EXPERIMENTAL; Interventions: Drug: mycophenolate mofetil | Arm Label: cyclophosphamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: cyclophosphamide | Intervention Type: DRUG; Name: mycophenolate mofetil; Assigned to Arm(s): mycophenolate mofetil | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): cyclophosphamide
C: Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Prednisone (and methylprednisolone); Assigned to Arm(s): N/A
D: Arm Label: A; Type: OTHER; Interventions: Drug: prednisone, methylprednisolone,cyclophosphamides, Drug: Mycophenolate mofetil,methotrexate | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone, Drug: Mycophenolate mofetil,methotrexate | Intervention Type: DRUG; Name: prednisone, methylprednisolone,cyclophosphamides; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Mycophenolate mofetil,methotrexate; Assigned to Arm(s): A, B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Immunoglobulin After Relapse in Vasculitis (Microscopic Polyangiitis, Wegener's Granulomatosis and SHURG-STRAUSS Syndrome) During and After Corticosteroids and Immunosuppressant Therapies a Multicenter Prospective Trial
Brief Summary: The aim of this study is to study the efficacy of intravenous immunoglobulins for inducing remission in patients relapsing of systemic vasculitides.


Options:
A: Intervention Type: DRUG; Name: Intravenous immunoglobulins (human immunoglobulins G); Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: azathioprine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Azathioprine: 2 mg/kg/day; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without Immunosuppressants
Brief Summary: The aim of this trial is to lower the morbidity rate in elderly patients affected with systemic necrotizing vasculitides, by reducing mortality and improving global outcome.


Options:
A: Arm Label: A; Type: OTHER; Interventions: Drug: prednisone, methylprednisolone,cyclophosphamides, Drug: Mycophenolate mofetil,methotrexate | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone, Drug: Mycophenolate mofetil,methotrexate | Intervention Type: DRUG; Name: prednisone, methylprednisolone,cyclophosphamides; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Mycophenolate mofetil,methotrexate; Assigned to Arm(s): A, B
B: Arm Label: Placebo plus azathioprine; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Azathioprine | Arm Label: Belimumab 10 mg/kg plus azathioprine; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 10 mg/kg, Drug: Azathioprine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo plus azathioprine | Intervention Type: BIOLOGICAL; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg plus azathioprine | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Belimumab 10 mg/kg plus azathioprine, Placebo plus azathioprine
C: Arm Label: azathioprine, standard; Type: ACTIVE_COMPARATOR; Interventions: Drug: azathioprine | Arm Label: azathioprine, longterm; Type: EXPERIMENTAL; Interventions: Drug: azathioprine | Intervention Type: DRUG; Name: azathioprine; Assigned to Arm(s): azathioprine, longterm, azathioprine, standard
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: Plasma exchange | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous methyl prednisolone, Drug: Methyl prednisolone | Intervention Type: PROCEDURE; Name: Plasma exchange; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Intravenous methyl prednisolone; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methyl prednisolone; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Body-weight Supported Therapy Using Gait Trainer Versus Traditional Gait-oriented Physiotherapy in Acute Phase of Stroke. The Effectiveness of Gait Training and Brain Networks Using NBS (Navigating Brain Stimulation)
Brief Summary: This is a trial aiming to evaluate the difference of effectiveness between two therapy methods in patients with acute stroke. The other aim is to use Navigated Brain Stimulation (NBS)to analyze changes in brain networks during the recovery and as the consequence of rehabilitation. The groups are:

* body-weight supported gate trainer rehabilitation
* gait-oriented traditional physiotherapy Patients in physiotherapy group will have 75 min physiotherapy daily every workday. This includes 20 minutes walking exercises in the traditional group while 20 minutes of gait trainer therapy in the gait trainer group. The evaluation of effectiveness of therapy in each group is made after three weeks' therapy and at six months. The goal is to have 40 patients until the end of June 2006.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: intensified gait trainer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: intensified gait trainer | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: intensified gait trainer; Assigned to Arm(s): 1, 2
B: Intervention Type: PROCEDURE; Name: exercise therapy; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: walking rehabilitation; Assigned to Arm(s): N/A
C: Arm Label: Early Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Early locomotor training program | Arm Label: Late Locomotor Training Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Late locomotor training program | Arm Label: Early Home Exercise Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Home Exercise Program | Intervention Type: BEHAVIORAL; Name: Early locomotor training program; Assigned to Arm(s): Early Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Late locomotor training program; Assigned to Arm(s): Late Locomotor Training Program | Intervention Type: BEHAVIORAL; Name: Home Exercise Program; Assigned to Arm(s): Early Home Exercise Program
D: Arm Label: Static surface; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Static surface | Arm Label: dynamic surface; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Dynamic surface | Intervention Type: PROCEDURE; Name: Static surface; Assigned to Arm(s): Static surface | Intervention Type: PROCEDURE; Name: Dynamic surface; Assigned to Arm(s): dynamic surface

Answer: A